Certificate Course in Veterinary Pharmacovigilance

Define the pharmacovigilance scope by aligning resources, including IT tools, people, and funding, with anticipated adverse event reports, product coverage, and non-local reporting, including expedited and PSU requirements.

Draft a flexible legislation framework for veterinary pharmacovigilance, clarifying roles and responsibilities of authorities, marketing authorisation holders, and veterinarians. Provide guidelines that evolve with experience for reporting and risk management.

Set up a veterinary pharmacovigilance system by defining scope, resources, funding, and legislative guidance, then scale incrementally with stakeholder engagement and standardized documentation.

Harmonize local pharmacovigilance with internationally standardized adverse event formats and language alignment to Vedra terminology, enabling exchange and reducing non-value-added administrative work.

Define roles and responsibilities for the national competent authority, local authorities, and marketing authorisation holders to ensure veterinary pharmacovigilance, qppv duties, and clear reporting pathways by veterinarians.

Establish and publish veterinary pharmacovigilance documentation and systems, including procedures, adverse event reporting forms, minimum core data set, case numbering, causality assessment, and stakeholder consultation for regulatory actions.

Plan internal staff training to establish an early pharmacovigilance system, assigning responsibilities and ensuring consistent procedures. Provide initial and refresher training with materials and backup support to sustain compliance.

Develop a communication and awareness plan for veterinarians, users, and animal owners to promote pharmacovigilance, outline obligations, provide accessible reporting forms, and engage distributors and retailers through the NCI website.

Regional cooperation strengthens pharmacovigilance by enabling data sharing and resource optimization, especially for small markets with low reporting, during the system’s initial setup.

Education promotes veterinary pharmacovigilance by engaging veterinarians, veterinary technicians, and trainees, with the national competent authority, marketing authorisation holders, animal owners, diagnostic labs, and academics collaborating to encourage reporting.

Publish a report to provide feedback to veterinarians and veterinary technicians, encourage two-way dialogue, and summarize actions with descriptive statistics to show reporting value and guide publicity materials for websites.

Promote pharmacovigilance by making adverse event reporting easy through clear NCA and MH channels, responsive follow-ups, and ongoing outreach and training for veterinarians and owners.

Learn the standard content and four minimum criteria for veterinary adverse event reports, including identifiable reporter, animal or human, veterinary product, adverse signs, and acceptable English and local languages.

Provide access to adverse event reports for animal owners, veterinarians, and other stakeholders via printable and electronic reporting forms on regulatory authority or professional organization websites.

Process spontaneous adverse event reports by assigning case numbers, confirming receipt, following up, storing and recording data with GL 30, GL 35, and GL 42, and coding and causality assessment.

Record, store, and archive pharmacovigilance data to support coding, assessment, and reporting, noting that individual adverse event submission timelines vary from 15 to 30 calendar days by country or region.

Apply Vedra terminology to veterinary pharmacovigilance by coding adverse event reports with the Vedra dictionary for humans and animals. Use Hedera to describe events in a standardized format.

Assess causality of adverse events after veterinary medicinal products by evaluating temporal association, pharmacological and immunological explanations, and data completeness, then apply modified Cramer and airborne scoring to classify links.

Store pharmacovigilance data electronically with access controls and fire, water or theft protections, using an international standards format veterinary database that supports reporting, data exchange, archival storage, and analysis procedures.

Learn archival periods for pharmacovigilance data of veterinary medicines, including MHRA two years after expiry and NCA three years after marketing authorisation expires.

Review the veterinary adverse event report form for safety reporting. Reporters include veterinarians, consumers, or animal owners with initial or follow-up designation after using a veterinary medicinal product.

Learn about periodic summary update reports ( PSU ) for veterinary medicinal products, detailing scope, frequency, and content per VICH GL 29, and defining IBD and data lock point ( DLP ).

Identify the PSU language requirement, establishing English as the global PSU language, with translations up to 90 days when local language is required, and no translations for third country cases.

Explain the periodic summary update report contents, including adverse events, bibliographic and exposure data, regulatory actions, and a concise benefit-risk assessment with Kramer or Avon causality and vadiraj-coded line listings.

Analyze aggregated pharmacovigilance data using meaningful intervals and comparable periods; tailor methods to adverse event counts, differentiating serious versus non-serious events and on-label versus off-label use.

Apply a risk-based timeframes approach for aggregate data analysis and periodic reports, prioritizing serious or new adverse effects; begin half-yearly reviews post-authorization and adjust as safety profiles mature.

Signal management in veterinary pharmacovigilance detects signals, validates them, and prioritizes by potential severity, distinguishing potential from identified risks and guiding risk-based mitigation.

Apply a risk-based management plan in veterinary pharmacovigilance to address identified and potential risks, implement follow-up regulatory measures and mitigation actions, and harmonize safety communications to preserve the benefit-risk balance.

Communicate pharmacovigilance outcomes to veterinarians, health professionals, and the public with context and risk management, coordinating with authorities and industry to ensure timely, clear safety information.

Explore audits and inspections in veterinary pharmacovigilance, including internal audits, CAPA, risk-based planning, and the responsibilities of the marketing authorisation holder and national competent authorities for quality management systems.

Retrieve your completion certificate from your profile and share it on LinkedIn. Access downloadable training slides, Q&A support, and explore related pharmacovigilance courses such as aggregate reporting and risk management.